Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

489 - Phase III SafeHer study subgroup analyses: Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Mona Shing

Citation

Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519

Authors

K.H. Jung1, B. Ataseven2, M. Verrill3, M. De Laurentiis4, H.A. Azim5, X. Pivot6, N. Al-Sakaff7, S. Lauer8, M. Shing9, J. Gligorov10

Author affiliations

  • 1 Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 2 Department Of Obstetrics And Gynaecology, Kliniken Essen-Mitte, 45136 - Essen/DE
  • 3 Medical Oncology Department, Northern Centre for Cancer Care, NE7 7DN - Newcastle upon Tyne/GB
  • 4 Breast Oncology Department, National Cancer Institute “Fondazione Pascale”, Naples/IT
  • 5 Clinical Oncology Department, Cairo University, Cairo/EG
  • 6 Chemotherapy - Oncology, CHU Jean Minjoz, 25030 - Besançon/FR
  • 7 Global Pharma Development, F. Hoffmann-La Roche Ltd., CH-4070 - Basel/CH
  • 8 Biostatistics, F. Hoffmann-La Roche Ltd., CH-4070 - Basel/CH
  • 9 Global Pharma Development, Genentech Inc., 94080 - San Francisco/US
  • 10 Aphp Hôpital Tenon And Upmc, Institut Universitaire de Cancérologie, Université Paris-Sorbonne, 75020 - Paris/FR
More

Resources

Abstract 489

Aim/Background

To explore safety and tolerability of 600 mg fixed-dose subcutaneous (SC) trastuzumab (Herceptin® SC [H SC]), administered every 3 weeks (q3w) for 18 cycles via hand-held syringe, as adjuvant therapy for HER2-positive early breast cancer (EBC) in patients (pts) with lower body weight and in Asian pts in Cohort A of the SafeHer study. Pts in Cohort B receive H SC via single-use injection device and treatment was ongoing at the time of clinical cutoff.

Methods

Adverse events (AEs) and serious AEs (SAEs) were recorded/graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) 4.0; congestive heart failure (CHF), according to NCI-CTCAE 4.0/New York Heart Association functional classification. Lower-weight subgroups were pts weighing <45 kg, ≤53 kg (lowest weight decile) and ≤59 kg (lowest weight quartile). Results are from a planned interim analysis; follow-up will continue for 5 years.

Results

SafeHer interim results are from the first dose until 4 weeks after the last H SC dose (13 months' follow-up for pts who received 18 H SC cycles). Cohort A's safety population comprises 1864 pts; 1563 (84%) received 18 H SC cycles and 295 (16%) are Asian. Among the 31 pts weighing <45 kg, the 226 pts weighing ≤53 kg and the 501 pts weighing ≤59 kg, there was a greater proportion of Asian pts compared with the overall population (55%, 43% and 34%, respectively, compared with 16%). Overall safety, safety in lower-weight groups and safety in Asian pts are shown in the table.

Pts, n (%) Cohort A overall n = 1864 <45 kg n = 31 Lowest weight decile: ≤53 kg n = 226 Lowest weight quartile: ≤59 kg n = 501 Asian pts n = 295
Any grade AE 1628 (87) 27 (87) 197 (87) 428 (85) 254 (86)
≥grade 3 AE 432 (23) 8 (26) 40 (18) 89 (18) 48 (16)
SAE 235 (13) 3 (10) 25 (11) 51 (10) 33 (11)
Cardiac AE 310 (17) 5 (16) 24 (11) 58 (12) 38 (13)
CHF 10 (1) 0 2 (1) 4 (1) 4 (1)

Conclusions

In this SafeHer Phase III study subgroup analysis, the safety results were similar for the H SC 600 mg q3w fixed dose among lower-weight and Asian pts, relative to the overall population. Thus, safety and tolerability of the H SC 600 mg q3w fixed dose is confirmed as adjuvant therapy for these important HER2-positive EBC pt populations.

Clinical trial identification

NCT01566721

Disclosure

M. Shing: Other Substantive Relationships - Genentech employee. K.H. Jung: Corporate-sponsored Research - Eisai Korea. B. Ataseven, H.A. Azim, J. Gligorov: Advisory Board - Roche; Corporate-sponsored Research – Roche. M. Verrill: Advisory Board ‐ Fees from Roche; Corporate‐sponsored Research ‐ Institutional funding from Roche; Other Substanstve Relationships ‐ Fees from speaking for Roche. M. De Laurentiis: Advisory Board - Novartis, Roche, Celgene, AstraZeneca, Genomic Health. N. Al-Sakaff: Ownership - Roche shares; Other Substantive Relationships - Roche employee. S. Lauer: Other Substantive Relationships - Roche contractor. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings